UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

OIPE
SEP 16 2003
PATENT & TRADEMARK OFFICE C21

RECEIVED
SEP 16 2003
TECH CENTER 1600/2900

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/647,457	11/29/2000	Meir Shinitzky	24390	6935

20529 7590 07/08/2003

NATH & ASSOCIATES
1030 15th STREET
6TH FLOOR
WASHINGTON, DC 20005

EXAMINER
TURNER, SHARON L

ART UNIT	PAPER NUMBER
1647	

DATE MAILED: 07/08/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

09/647,457

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

OIPE
SEP 16 2003
PATENT & TRADEMARK OFFICE
JC21

RECEIVED
SEP 26 2003
TECH CENTER 1600/2900

EXAMINER	
ART UNIT	PAPER NUMBER

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Turner whose telephone number is (703) 308-0056. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Gary Kunz whose telephone number is (703) 308-4623. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Sharon Turner
7-7-03

Application No.

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

OIPE JC21
SEP 16 2003
PATENT & TRADEMARK OFFICE

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

RECEIVED
SEP 26 2003
TECH CENTER 1600/2900

☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1148 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☒ 7. Other: All sequences within claims and specification must be referenced by appropriate SEQ ID NO:

Applicant Must Provide:

☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVE
APR 25 2003
TECH CENTER 1600/2900
RECEIVED
SEP 26 2003
TECH CENTER 1600/2900

BIOTECHNOLOGY SYSTEMS BRANCH



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/647,457B
Source: 1600
Date Processed by STIC: 4/21/03

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN ASSISTANCE: e-mail: robert.wax @ uspto.gov Telephone: 703-306-4119

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:
http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
   EFFECTIVE MAY 1, 2003 (via USPS): Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry directly to:
   U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
   Or
   U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 04/01/2003

1600

Raw Sequence Listing Error Summary

ERROR DETECTED | SUGGESTED CORRECTION | SERIAL NUMBER: 09/647,457B

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1____ Wrapped Nucleics / Wrapped Aminos — The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2____ Invalid Line Length — The rules require that a line not exceed 72 characters in length. This includes white spaces.

3____ Misaligned Amino Numbering — The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4____ Non-ASCII — The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5 ✓ Variable Length — Sequence(s) 1 contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6____ PatentIn 2.0 "bug" — A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.

7____ Skipped Sequences (OLD RULES) — Sequence(s) ____ missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.

8____ Skipped Sequences (NEW RULES) — Sequence(s) ____ missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000

9____ Use of n's or Xaa's (NEW RULES) — Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10____ Invalid <213> Response — Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence

11____ Use of <220> — Sequence(s) ____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

12____ PatentIn 2.0 "bug" — Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13____ Misuse of n — n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

OIPE JC117
SEP 1 6 2003
PATENT & TRADEMARK OFFICE

1600

Does Not Comply
Corrected Diskette Needed

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003
TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt
Output Set: N:\CRF4\04212003\I647457B.raw

3 <110> APPLICANT: Yeda Research and Development Company Ltd.
5 <120> TITLE OF INVENTION: ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW PEPTIDE
7 <130> FILE REFERENCE: 1276302
9 <140> CURRENT APPLICATION NUMBER: 09/647,457B
10 <141> CURRENT FILING DATE: 2000-09-29
12 <150> PRIOR APPLICATION NUMBER: PCT/IL99/00190
13 <151> PRIOR FILING DATE: 1999-09-29
15 <150> PRIOR APPLICATION NUMBER: 123925
16 <151> PRIOR FILING DATE: 1998-04-02
18 <160> NUMBER OF SEQ ID NOS: 15
20 <170> SOFTWARE: PatentIn version 3.1
22 <210> SEQ ID NO: 1
23 <211> LENGTH: 17
24 <212> TYPE: PRT
25 <213> ORGANISM: Unknown
27 <220> FEATURE:
28 <223> OTHER INFORMATION: an isolated peptide which binds antibodies.
30 <220> FEATURE:
31 <221> NAME/KEY: MISC_FEATURE
32 <222> LOCATION: (1)..(17)
33 <223> OTHER INFORMATION: Xaa in position 1 may be SGETEDTFIAD IAD AD, D or may be absent;
34 Xaa in position 9 may be C, G, or P; Xaa in position 15 may be AP
35 , or PA; Xaa in position 17 may be R, or may be absent.
38 <400> SEQUENCE: 1
W--> 40 **Xaa Leu Val Val Gly Leu Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Cys**
41 1 5 10 15
44 Xaa
48 <210> SEQ ID NO: 2
49 <211> LENGTH: 28
50 <212> TYPE: PRT
51 <213> ORGANISM: Unknown
53 <220> FEATURE:
54 <223> OTHER INFORMATION: being the immunologically active epitope
56 <400> SEQUENCE: 2
58 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
59 1 5 10 15
62 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
63 20 25
66 <210> SEQ ID NO: 3
67 <211> LENGTH: 16
68 <212> TYPE: PRT
69 <213> ORGANISM: Unknown

variable length — p/s see error summary sheet item 5

.71 <220> FEATURE:

OIPE SEP 16 2003 JC21 PATENT & TRADEMARK OFFICE

RAW SEQUENCE LISTING DATE: 04/21/2003
PATENT APPLICATION: US/09/647,457B TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt
Output Set: N:\CRF4\04212003\I647457B.raw

72 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated
73 levels in body fluids of schizophrenic patients.
75 <400> SEQUENCE: 3
77 Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys
78 1 5 10 15
81 <210> SEQ ID NO: 4
82 <211> LENGTH: 20
83 <212> TYPE: PRT
84 <213> ORGANISM: Unknown
86 <220> FEATURE:
87 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated
88 levels in body fluids of schizophrenic patients.
90 <400> SEQUENCE: 4
92 Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly
93 1 5 10 15
96 Ala Pro Cys Arg
97 20
100 <210> SEQ ID NO: 5
101 <211> LENGTH: 19
102 <212> TYPE: PRT
103 <213> ORGANISM: Unknown
105 <220> FEATURE:
106 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated
107 levels in body fluids of schizophrenic patients
109 <400> SEQUENCE: 5
111 Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala
112 1 5 10 15
115 Pro Cys Arg
119 <210> SEQ ID NO: 6
120 <211> LENGTH: 18
121 <212> TYPE: PRT
122 <213> ORGANISM: Unknown
124 <220> FEATURE:
125 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated
126 levels in body fluids of schizophrenic patients
128 <400> SEQUENCE: 6
130 Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
131 1 5 10 15
134 Cys Arg
138 <210> SEQ ID NO: 7
139 <211> LENGTH: 17
140 <212> TYPE: PRT
141 <213> ORGANISM: Unknown
143 <220> FEATURE:
144 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated
145 levels in body fluids of schizophrenic patients
147 <400> SEQUENCE: 7
149 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys

150 1 5 10 15

RAW SEQUENCE LISTING DATE: 04/21/2003
PATENT APPLICATION: US/09/647,457B TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt
Output Set: N:\CRF4\04212003\I647457B.raw

153 Arg
157 <210> SEQ ID NO: 8
158 <211> LENGTH: 17
159 <212> TYPE: PRT
160 <213> ORGANISM: Unknown
162 <220> FEATURE:
163 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated
164 levels in body fluids of schizophrenic patients
166 <400> SEQUENCE: 8
168 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
169 1 5 10 15
172 Arg
176 <210> SEQ ID NO: 9
177 <211> LENGTH: 17
178 <212> TYPE: PRT
179 <213> ORGANISM: Unknown
181 <220> FEATURE:
182 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated
183 levels in body fluids of schizophrenic patients
185 <400> SEQUENCE: 9
187 Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys
188 1 5 10 15
191 Arg
195 <210> SEQ ID NO: 10
196 <211> LENGTH: 20
197 <212> TYPE: PRT
198 <213> ORGANISM: Unknown
200 <220> FEATURE:
201 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated
202 levels in body fluids of schizophrenic patients
204 <400> SEQUENCE: 10
206 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
207 1 5 10 15
210 Cys Thr Gly Gln
211 20
214 <210> SEQ ID NO: 11
215 <211> LENGTH: 16
216 <212> TYPE: PRT
217 <213> ORGANISM: Unknown
219 <220> FEATURE:
220 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated
221 levels in body fluids of schizophrenic patients
223 <400> SEQUENCE: 11
225 Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
226 1 5 10 15
229 <210> SEQ ID NO: 12
230 <211> LENGTH: 12
231 <212> TYPE: PRT
232 <213> ORGANISM: Unknown

RAW SEQUENCE LISTING DATE: 04/21/2003
PATENT APPLICATION: US/09/647,457B TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt
Output Set: N:\CRF4\04212003\I647457B.raw

```
234 <220> FEATURE:
235 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
236       levels in body fluids of schizophrenic patients
238 <400> SEQUENCE: 12
240 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
241 1               5                   10
244 <210> SEQ ID NO: 13
245 <211> LENGTH: 16
246 <212> TYPE: PRT
247 <213> ORGANISM: Unknown
249 <220> FEATURE:
250 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
251       levels in body fluids of schizophrenic patients
253 <400> SEQUENCE: 13
255 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
256 1               5                   10                  15
259 <210> SEQ ID NO: 14
260 <211> LENGTH: 15
261 <212> TYPE: PRT
262 <213> ORGANISM: Unknown
264 <220> FEATURE:
265 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
266       levels in body fluids of schizophrenic patients
268 <400> SEQUENCE: 14
270 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
271 1               5                   10                  15
274 <210> SEQ ID NO: 15
275 <211> LENGTH: 16
276 <212> TYPE: PRT
277 <213> ORGANISM: Unknown
279 <220> FEATURE:
280 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
281       levels in body fluids of schizophrenic patients
283 <400> SEQUENCE: 15
285 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
286 1               5                   10                  15
```

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 04/21/2003
PATENT APPLICATION: US/09/647,457B TIME: 15:22:39

Input Set : A:\1276302.1.ST25.txt
Output Set: N:\CRF4\04212003\I647457B.raw

Please Note:
Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1,9,15,17

VERIFICATION SUMMARY DATE: 04/21/2003
PATENT APPLICATION: US/09/647,457B TIME: 15:22:39

Input Set : A:\1276302.1.ST25.txt
Output Set: N:\CRF4\04212003\I647457B.raw

L:40 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
M:341 Repeated in SeqNo=1